BioLineRx (NASDAQ:BLRX) Announces Earnings Results

BioLineRx (NASDAQ:BLRX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07, Zacks reports. The firm had revenue of $4.80 million for the quarter, compared to the consensus estimate of $0.17 million. During the same quarter last year, the firm earned ($0.09) EPS.

BioLineRx Stock Up 0.9 %

NASDAQ:BLRX traded up $0.01 during mid-day trading on Friday, reaching $1.12. The company’s stock had a trading volume of 163,193 shares, compared to its average volume of 342,065. BioLineRx has a 1 year low of $0.81 and a 1 year high of $2.53. The stock has a fifty day moving average of $1.20 and a 200-day moving average of $1.46. The firm has a market capitalization of $81.13 million, a PE ratio of -1.24 and a beta of 1.40. The company has a quick ratio of 1.86, a current ratio of 1.53 and a debt-to-equity ratio of 0.50.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. StockNews.com raised shares of BioLineRx to a “sell” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Tuesday.

Hedge Funds Weigh In On BioLineRx

A number of large investors have recently added to or reduced their stakes in BLRX. Renaissance Technologies LLC raised its holdings in BioLineRx by 278.0% in the fourth quarter. Renaissance Technologies LLC now owns 257,900 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 189,678 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of BioLineRx during the first quarter valued at about $178,000. Envestnet Asset Management Inc. acquired a new position in shares of BioLineRx during the first quarter valued at about $88,000. Finally, LPL Financial LLC increased its holdings in shares of BioLineRx by 152.7% during the fourth quarter. LPL Financial LLC now owns 117,710 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 71,134 shares in the last quarter. 1.56% of the stock is currently owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.